Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "LivaNova"


5 mentions found


Goldman Sachs says a period of underperformance for LivaNova stock could be ending and see shares gain more than 20%. Roman initiated coverage of the medical device stock with a buy rating and a $65 per share price target. Shares have advanced roughly 3% in 2024, significantly underperforming the S & P 500's nearly 20% gain. Roman ties the underperformance to "strategic shifts in the business and pipeline setbacks" for much of the year which also pressured LivaNova's earnings. LIVN YTD mountain LivaNova stock.
Persons: Goldman Sachs, David Roman, LivaNova
Here are Tuesday's biggest calls on Wall Street: Morgan Stanley downgrades Oatly to equal weight from overweight Morgan Stanley resumed coverage of the oats company and said it sees too many negative catalysts. " Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's sticking with Tesla despite a slew of negative data points in a recent investor survey. Morgan Stanley reiterates Nvidia as overweight Morgan Stanley said it's standing by Nvidia heading into earnings later this week. Morgan Stanley initiates CG Oncology as buy Morgan Stanley said shares of the bladder cancer company are "compelling." "We initiate coverage on Morgan Stanley Direct Lending with a Buy rating and $23.50 PT.
Persons: Morgan Stanley downgrades Oatly, Morgan Stanley, Tesla, Bernstein, Siri, it's, Disney, Ingersoll Rand, Rosenblatt, MSCI's, Goldman Sachs, Wolfe, Piper Sandler, Riley, Grainger, Northcoast, JPMorgan downgrades Holley Organizations: Apple, Nvidia, Disney, RBC, Aerospace, BAE Systems, Caterpillar, SMCI, Deutsche Bank, JetBlue, Alaska Air, ASM, Health, BrightSpring Health, Brunswick Corporation, Barclays, JPMorgan, Mizuho, Oncology, UBS, Morgan, Fund, Seaport, Booking Holdings, " Bank of America, AIG, Bank of America, General Insurance Locations: Silicon Valley, Alaska, Brunswick, MIBS, Texas, Europe, Asia
CNBC Pro used FactSet data to scan the stock market to find the biggest winners of the week — and then looked to find out where Wall Street thinks these stocks are headed in coming months. One name that stuck out on the list was once-troubled regional bank PacWest Bancorp , which jumped almost 12% this week as of Friday morning. Wall Street believes shares have 55% upside, according to the consensus 12-month price target set by analysts. PacWest shares had a strong week after regional banking peer Western Alliance Bancorp posted quarterly adjusted earnings, according to FactSet. BJ's Restaurants ' stock rose 9.2% this week after Wedbush Securities upgraded shares to outperform from neutral.
Small-cap stocks could beat their large-cap counterparts in 2023, according to Jefferies. Equity strategist Steven DeSanctis said small-cap stocks have cheap relative valuations while volume has slid, high-yield spreads have tightened and cyclicals have been sold off. Expectations are low with poor sentiment for small caps, DeSanctis said. Taken together with the attractive valuations, improving merger and acquisition landscape and better macroenvironment, he said he believes small caps will outperform in 2023. Given this varied landscape, DeSanctis screened for smaller-cap stocks that have lagged year to date but do well in Jefferies' modeling.
Greenlight Capital's David Einhorn is in the middle of a stellar year as his inflation bets and other trades pay off. Green Brick Partners , a bet on rising housing prices, continued to be his biggest holding, a new regulatory filing showed. During the third quarter, Einhorn increased his stake in tech stock Kyndryl Holdings to $60 million. Meanwhile, the hedge fund manager added to his holding in LivaNova drastically, making the medical device company Greenlight's eighth biggest bet, the filing showed. Einhorn previously said he's bearish on equities as the Fed continues to deflate the market with aggressive rate hikes.
Total: 5